We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Snibe Co.,Ltd.

Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) is a global leader in the IVD field, with 30 years o... read more Featured Products: More products

Download Mobile App





SNIBE Brings Latest Innovations in Immunoassay, Clinical Biochemistry and Molecular Diagnostics to Medlab Middle East 2023

By LabMedica International staff writers
Posted on 09 Feb 2023

SNIBE (Shenzhen, China) is bringing its latest innovations, including new members from its product lines in immunoassay, clinical biochemistry and molecular diagnostics to Medlab Middle East 2023. More...

At Medlab Middle East 2023, SNIBE is showcasing Biolumi CX8, the new lab booster that combines one of the fastest immunoassay system MAGLUMI X8, and the biochemical system Biossays C8, with ultra-high throughput in a very small footprint. Moreover, it can also be customized according to specific needs, supporting up to four connected instruments, and covering the requirements of different laboratories. SNIBE is also showcasing the MAGLUMI X6 flexible CLIA solution that is designed for medium/high-volume laboratories. The MAGLUMI X6 offers flexible configuration modules and features new generation hydraulic TIP pipetting technology. It has a high speed of 450 tests/hour and is suitable for 155 chemiluminescence immunoreagents.

In addition, SNIBE is highlighting the Molecision S6 automated, integrated digital PCR system that provides a full-platform solution for research/in vitro diagnostics. Molecision S6 uses a cutting-edge cartridge that provides uniform droplets and prevents contamination, maximizing operation productivity and cost efficiency. Light oil is pre-filled in the cartridge so that the droplets can be sunk under the light oil to ensure a fully enclosed condition, achieving a sensitivity of 0.002%. Its highly integrated design and optimized system make it space-saving and easy to use. Alongside the Molecision S6, SNIBE is highlighting the Molecision MP-32 and MP-96 fully-auto nucleic acid purification systems that adopt a high-performance magnetic extraction method, thereby maximizing the recovery rate and consistency of results.

Related Links:
SNIBE


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Automatic CLIA Analyzer
Shine i6000
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.